Health News Roundup: J&J can contest evidence linking its talc to cancer, US judge rules; Novocure's device shown to slow cancer progression in the brain in trial and more

Former Holyoke Soldiers' Home Superintendent Bennett Walsh and former Medical Director David Clinton withdrew their previous not guilty pleas during hearings in Hampshire Superior Court and admitted there were facts sufficient to find them guilty of the charges against them, prosecutors said. US FDA approves Merck's therapy for rare lung condition The U.S. Food and Drug Administration on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio.

Following is a summary of current health news briefs.

Novocure's device shown to slow cancer progression in the brain in trial

Novocure's therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of lung cancer, the company said on Wednesday, sending the company's shares up 17%. The therapy, which uses a device, slowed the spread of cancer in the brain to 21.9 months, along with supportive care, compared to 11.3 months for supportive care alone in patients with non-small cell lung cancer (NSCLC), the company said in a statement.

Ex-leaders of Massachusetts veterans' home avoid prison over COVID outbreak

Two former leaders of a Massachusetts veterans' home that was the site of one of the deadliest COVID-19 outbreaks at a U.S. long-term care facility on Tuesday resolved criminal neglect charges against them without having to go to prison. Former Holyoke Soldiers' Home Superintendent Bennett Walsh and former Medical Director David Clinton withdrew their previous not-guilty pleas during hearings in Hampshire Superior Court and admitted there were facts sufficient to find them guilty of the charges against them, prosecutors said.

US FDA approves Merck's therapy for rare lung condition

The U.S. Food and Drug Administration on Tuesday approved Merck's treatment for adults with high blood pressure due to constriction of lung arteries, adding another potential blockbuster drug to the pharmaceutical giant's portfolio. Shares of Merck were up more than 4% in extended trading.

J&J can contest evidence linking its talc to cancer, US judge rules

Johnson & Johnson will get a new chance to contest the scientific evidence linking talc to ovarian cancer, a federal judge ruled on Wednesday, potentially disrupting more than 53,000 lawsuits the company is now facing over its talc products. In a brief written order, U.S. District Judge Michael Shipp in Trenton, New Jersey, who is overseeing the lawsuits that have been consolidated in his court, said recent changes in the law and new scientific evidence require a fresh review of the evidence that linked J&J products to ovarian cancer.

US Supreme Court appears skeptical of challenge to abortion pill access

The U.S. Supreme Court on Tuesday signaled that it is unlikely to limit access to the abortion pill as the justices appeared skeptical that the anti-abortion groups and doctors that are challenging the drug have the needed legal standing to pursue the case. The justices heard arguments in an appeal by President Joe Biden's administration of a lower court's ruling in favor of the plaintiffs that would limit how the medication, called mifepristone, is prescribed and distributed. The case places reproductive rights back on the Supreme Court's agenda in a presidential election year.

British satisfaction with healthcare drops to new low ahead of election

British satisfaction with the state-owned National Health Service (NHS) dropped to a record low for 2023, showing the challenge for the government over a key concern for voters ahead of an election expected this year. The British Social Attitudes survey found that 24% of people were satisfied with the service in 2023, five percentage points down from last year and the lowest level recorded since people were first asked in 1983.

Viking Therapeutics' weight-loss tablet shows promise in small study

Viking Therapeutics' experimental tablet reduced weight by as much as 3.3% when tested in volunteers enrolled in a small early-stage trial, meeting Wall Street expectations and sending the company's shares up 15% in premarket trading on Tuesday. Popular market leaders from Eli Lilly and Novo Nordisk are administered under the skin, with companies also testing oral versions that they hope will offer patients a more convenient option.

UnitedHealth Group paid over $3.3 billion to care providers hit by cyberattacks

U.S. insurer UnitedHealth Group on Wednesday said it has advanced more than $3.3 billion so far to care providers impacted by a cyberattack last month on insurance claims system Change Healthcare. UnitedHealth said it has paid more than 40% of that total to so-called safety net hospitals and federally qualified health centers serving high-risk patients and communities.

Boat Race rowers told to avoid the water as UK sewage dumping surges

Victorious rowers in Britain's University Boat Race have been warned not to jump into the River Thames this weekend due to alarming levels of E. coli bacteria, as official data showed sewage spills hit a record high in 2023. Regular dumping of raw sewage in rivers and seas has sparked anger in Britain, with privatized water companies accused of failing to invest in infrastructure, meaning they are routinely dumping sewage in waterways.

U.S. FDA approves Akebia's anemia drug

The U.S. Food and Drug Administration approved Akebia Therapeutics' drug, vadadustat, to treat anemia caused by chronic kidney disease (CKD) in dialysis patients, the drugmaker said on Wednesday. The drug will be available under the brand name Vafseo, it added.

(With inputs from agencies.)